COMPASS Pathways plc (NASDAQ:CMPS) Receives $33.60 Consensus PT from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $33.60.

A number of equities research analysts have commented on CMPS shares. Royal Bank of Canada reduced their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 1st. HC Wainwright decreased their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th. Finally, Maxim Group reduced their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 1st.

COMPASS Pathways Stock Down 0.5 %

Shares of COMPASS Pathways stock opened at $4.03 on Friday. The firm has a market cap of $275.74 million, a price-to-earnings ratio of -1.83 and a beta of 2.25. The stock’s 50-day moving average is $4.99 and its 200 day moving average is $6.18. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a one year low of $3.86 and a one year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same period in the prior year, the firm earned ($0.67) EPS. Equities research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the sale, the insider now owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. This represents a 27.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.25% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On COMPASS Pathways

A number of hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. raised its holdings in shares of COMPASS Pathways by 4.4% in the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after purchasing an additional 12,599 shares during the last quarter. Geode Capital Management LLC grew its position in COMPASS Pathways by 160.3% in the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock worth $266,000 after purchasing an additional 25,970 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in COMPASS Pathways in the 3rd quarter valued at about $131,000. Point72 Asset Management L.P. bought a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $371,000. Finally, Polar Asset Management Partners Inc. boosted its stake in shares of COMPASS Pathways by 83.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after buying an additional 258,000 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.